Literature DB >> 16435017

Fludarabine phosphate and melphalan: a reduced intensity conditioning regimen suitable for allogeneic transplantation that maintains the graft versus malignancy effect.

R K Dasgupta1, S Rule, P Johnson, J Davies, A Burnett, C Poynton, K Wilson, G M Smith, G Jackson, C Richardson, E Wareham, A C Stars, S M Tollerfield, G J Morgan.   

Abstract

Reduced intensity conditioning (RIC) for allogeneic stem cell transplantation allows stable donor cell engraftment with the maintenance of a graft versus malignancy effect. Many different regimens exist employing various combinations of chemotherapy, radiotherapy and T-cell depletion. We examined the role of non-T-cell depleted RIC regimens in 56 patients with haematological malignancies. Patients received fludarabine phosphate for 5 days (30 mg/m2 in 35 patients, 25 mg/m2 in 21 patients) and melphalan for 1 day (140 mg/m2 in 36 patients, 100 mg/m2 in 20 patients). Immunosuppression was with CyA alone in 33 patients and CyA/MTX in 23 patients. Twenty-four of the 26 patients with chimerism data showed >95% donor chimerism at 3 months post transplant. aGVHD occurred in 18% of patients receiving CyA/MTX compared to 53% of patients receiving CyA. The 100-day mortality rate was 0.16 (95%CI 0.08-0.28) and 1-year nonrelapse mortality was 0.24 (95%CI 0.13-0.38). Thirty-three patients remained alive and in CR at a median of 19 months post transplant (range 3-38 months). We have shown that patients transplanted with fludarabine phosphate, melphalan 100 mg/m2 and with CyA/MTX as post transplant immunosuppression can achieve good disease control with an acceptable level of toxicity. Further studies are required to confirm these findings.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16435017     DOI: 10.1038/sj.bmt.1705271

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

Review 1.  Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignancies.

Authors:  S Fadilah Abdul Wahid
Journal:  Int J Hematol       Date:  2013-04-13       Impact factor: 2.490

2.  Comparison of reduced conditionings combining fludarabine with melphalan or 3-day busulfan in patients allografted for myeloid neoplasms.

Authors:  Ludek Raida; Zuzana Rusinakova; Edgar Faber; Romana Szotkowska; Peter Rohon; Ivana Skoumalova; Martina Divoka; Zuzana Pikalova; Karel Indrak; Katerina Langova
Journal:  Int J Hematol       Date:  2014-10-11       Impact factor: 2.490

3.  Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

Authors:  Fatima Bawany; Bushra Tbakhi; Jason H Mendler; Christopher T Richardson; John M Bennett; Omar S Aljitawi
Journal:  Blood Adv       Date:  2020-11-24

Review 4.  Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).

Authors:  S Abdul Wahid Fadilah; Md Pazil Aqilah
Journal:  Stem Cell Rev Rep       Date:  2012-12       Impact factor: 5.739

5.  CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.

Authors:  S G Holtan; W J Hogan; M A Elliott; S M Ansell; D J Inwards; L F Porrata; P B Johnston; I N Micallef; M Q Lacy; D A Gastineau; M R Litzow
Journal:  Bone Marrow Transplant       Date:  2010-03-08       Impact factor: 5.483

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.